Logo image of BGMSP

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BGMSP - US23254L2079

4.17 USD
+0.42 (+11.2%)
Last: 12/5/2025, 8:04:46 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BGMSP. BGMSP was compared to 531 industry peers in the Biotechnology industry. While BGMSP seems to be doing ok healthwise, there are quite some concerns on its profitability. BGMSP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BGMSP had negative earnings in the past year.
In the past year BGMSP has reported a negative cash flow from operations.
BGMSP had negative earnings in each of the past 5 years.
BGMSP had a negative operating cash flow in each of the past 5 years.
BGMSP Yearly Net Income VS EBIT VS OCF VS FCFBGMSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -85.49%, BGMSP is doing worse than 70.81% of the companies in the same industry.
BGMSP has a Return On Equity of -98.28%. This is comparable to the rest of the industry: BGMSP outperforms 46.70% of its industry peers.
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BGMSP Yearly ROA, ROE, ROICBGMSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BGMSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGMSP Yearly Profit, Operating, Gross MarginsBGMSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

BGMSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BGMSP has been increased compared to 1 year ago.
The number of shares outstanding for BGMSP has been increased compared to 5 years ago.
BGMSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGMSP Yearly Shares OutstandingBGMSP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
BGMSP Yearly Total Debt VS Total AssetsBGMSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

BGMSP has an Altman-Z score of -67.60. This is a bad value and indicates that BGMSP is not financially healthy and even has some risk of bankruptcy.
BGMSP has a Altman-Z score of -67.60. This is amonst the worse of the industry: BGMSP underperforms 94.16% of its industry peers.
There is no outstanding debt for BGMSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -67.6
ROIC/WACCN/A
WACC8.78%
BGMSP Yearly LT Debt VS Equity VS FCFBGMSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

BGMSP has a Current Ratio of 6.43. This indicates that BGMSP is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.43, BGMSP is doing good in the industry, outperforming 65.72% of the companies in the same industry.
BGMSP has a Quick Ratio of 5.07. This indicates that BGMSP is financially healthy and has no problem in meeting its short term obligations.
BGMSP has a Quick ratio of 5.07. This is comparable to the rest of the industry: BGMSP outperforms 56.87% of its industry peers.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 5.07
BGMSP Yearly Current Assets VS Current LiabilitesBGMSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

BGMSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.34%, which is quite impressive.
BGMSP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.46%.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%

3.2 Future

BGMSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.16% yearly.
BGMSP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1049.89% yearly.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A

3.3 Evolution

BGMSP Yearly Revenue VS EstimatesBGMSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2023 2024 2025 2026 2027 20M 40M 60M 80M
BGMSP Yearly EPS VS EstimatesBGMSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10K -20K -30K -40K -50K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGMSP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGMSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGMSP Price Earnings VS Forward Price EarningsBGMSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGMSP Per share dataBGMSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

BGMSP's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

5

5. Dividend

5.1 Amount

BGMSP has a Yearly Dividend Yield of 10.79%, which is a nice return.
BGMSP's Dividend Yield is rather good when compared to the industry average which is at 66.57. BGMSP pays more dividend than 99.81% of the companies in the same industry.
BGMSP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
Industry RankSector Rank
Dividend Yield 10.79%

5.2 History

The dividend of BGMSP decreases each year by -37.21%.
BGMSP has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-37.21%
Div Incr YearsN/A
Div Non Decr YearsN/A
BGMSP Yearly Dividends per shareBGMSP Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.1 0.2 0.3 0.4 0.5

5.3 Sustainability

DPN/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
BGMSP Yearly Income VS Free CF VS DividendBGMSP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

More info and screens

BIO GREEN MED SOLUTION - BGMS 6 PERP

NASDAQ:BGMSP (12/5/2025, 8:04:46 PM)

4.17

+0.42 (+11.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-31 2026-03-31/amc
Inst Owners0.12%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner ChangeN/A
Market Cap20.43M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %0.02%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield 10.79%
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date10-20 2025-10-20 (0.15)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 252.26
P/FCF N/A
P/OCF N/A
P/B 2.88
P/tB 3.7
EV/EBITDA N/A
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 5.07
Altman-Z -67.6
F-Score5
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ

What is the fundamental rating for BGMSP stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGMSP.


What is the valuation status for BGMSP stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP). This can be considered as Overvalued.


What is the profitability of BGMSP stock?

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for BGMSP stock?

The Earnings per Share (EPS) of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is expected to grow by 39.49% in the next year.